TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16798652

Group type: EXPERIMENTAL
Intervention: Combined therapy of deferiprone (L1) daily plus desferrioxamine (DFO) twice weekly
Number of subjects: 49

Group type: COMPARATOR
Intervention: DFO alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: L1 only
Number of subjects: 49
Study: 15541087

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Betamethasone 17-valerate 0.1% cream
Number of subjects: 20
Study: 11273943

Group type: COMPARATOR
Intervention: 8 mg hyperbaric tetracaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4 mg hyperbaric tetracaine, 10 microg fentanyl, and 0.2 mg epinephrine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4 mg hyperbaric tetracaine, 10 microg fentanyl, and 0.2 mL saline
Number of subjects: 45
Study: 9471147

Group type: EXPERIMENTAL
Intervention: Histologic total iron score (TIS)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Coefficient of heterogeneity
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Corrected total iron score (corTIS)
Number of subjects: 254
Study: 8387662

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: COMPARATOR
Intervention: Codeine 60 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg (pretreatment)
Number of subjects: 81
Study: 3475987

Group type: EXPERIMENTAL
Intervention: Low dose droperidol (0.25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose droperidol (0.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29412666

Group type: EXPERIMENTAL
Intervention: Water-saturated bulk EmimNTf2
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Poly(ether sulfone) SILM with water-saturated RTIL
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dry EmimNTf2
Number of subjects: 2
Study: 28746224

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver (RM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No alveolar recruitment maneuver (non-RM)
Number of subjects: 24
Study: 26306650

Group type: EXPERIMENTAL
Intervention: Sarcosine (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 50
Study: 23122597

Group type: EXPERIMENTAL
Intervention: Dual task group (mental arithmetic task)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 21402650

Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy for seven weeks
Number of subjects: 28
Study: 18482111

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Mandibular non-advancement appliance (MNA)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MAA
Number of subjects: 93
Study: 16528186

Group type: EXPERIMENTAL
Intervention: Cortical stimulation plus rehabilitation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (rehabilitation only)
Number of subjects: 10
Study: 14733349

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave treatments (ESW)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo (sham control)
Number of subjects: 435
Study: 10657406

Group type: EXPERIMENTAL
Intervention: GV150526 (800 mg loading dose followed by 200 mg every 12 hours for 3 days)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: GV150526
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 9092005

Group type: EXPERIMENTAL
Intervention: Technological advances and socioeconomic changes in health care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of basic research in departments of cardiology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selection of new technologies in terms of cost-effectiveness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocols, recommendations, and consensus
Number of subjects: 0
Study: 8422658

Group type: EXPERIMENTAL
Intervention: Oral physostigmine (OP) 16 mg/day for 6 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3020227

Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg q.i.d.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg q.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30104729

Group type: EXPERIMENTAL
Intervention: Intervention: Advice to consume more vegetables
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control: Baseline vegetable intake
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intervention: Top vegetable categories
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intervention: Vegetable consumption after 3 months
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intervention: Long-term vegetable consumption
Number of subjects: 113
Study: 27289163

Group type: EXPERIMENTAL
Intervention: Meal containing 10 g of extra virgin olive oil (EVOO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Meal without extra virgin olive oil (EVOO)
Number of subjects: 30
Study: 25281778

Group type: EXPERIMENTAL
Intervention: 5 mg solifenacin daily
Number of subjects: 640

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study: 23816489

Group type: EXPERIMENTAL
Intervention: General health promotion intervention
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Sexual risk reduction intervention
Number of subjects: 1010

Group type: COMPARATOR
Intervention: General health survey assessment
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Sexual health survey assessment
Number of subjects: 1010
Study: 21499206

Group type: EXPERIMENTAL
Intervention: Secretin (16 μg administered intravenously before ERCP)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 869
Study: 19156477

Group type: EXPERIMENTAL
Intervention: Attenuation correction (AC) with small field of view (SFOV) camera
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Attenuation correction (AC) with large field of view (LFOV) camera
Number of subjects: 78

Group type: COMPARATOR
Intervention: No attenuation correction (AC) with SFOV camera
Number of subjects: 78

Group type: COMPARATOR
Intervention: No attenuation correction (AC) with LFOV camera
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Attenuation correction (AC)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No attenuation correction (AC)
Number of subjects: 78
Study: 17293736

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator therapy in patients with NYHA class II HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator therapy in patients with NYHA class III HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone drug therapy in patients with NYHA class III HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic medical management
Number of subjects: 0
Study: 15228214

Group type: EXPERIMENTAL
Intervention: Ingestion of beta‐conglycinin (5 g daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ingestion of beta‐conglycinin
Number of subjects: 41
Study: 10656354

Group type: EXPERIMENTAL
Intervention: Hubs with hub protection boxes
Number of subjects: 137

Group type: COMPARATOR
Intervention: Hubs with needleless closed connectors
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 137
Study: 10178672

Group type: EXPERIMENTAL
Intervention: PC-BC/4
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PC-BC/5 (Biopack Compoflex)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PC-BC/5 (Optipac)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pooling of BCs
Number of subjects: 40
Study: 7870963

Group type: EXPERIMENTAL
Intervention: Active gum + active patch (double active)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Active gum + placebo patch (gum only active)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Placebo gum + active patch (patch active)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo gum + placebo patch (double placebo)
Number of subjects: 28
Study: 3488674

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 31261373

Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study: 30541604

Group type: EXPERIMENTAL
Intervention: Thread-embedding acupuncture (TEA), administered once every 2 weeks for 8 weeks (4 sessions total)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acupuncture, administered twice per week for 8 weeks (16 sessions total)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 40
Study: 26856224

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) and PCI
Number of subjects: 1826
Study: 24636118

Group type: EXPERIMENTAL
Intervention: Group-based lifestyle sessions (GBLS) during prenatal care visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-based lifestyle sessions (GBLS) off-site
Number of subjects: 0
Study: 22078221

Group type: EXPERIMENTAL
Intervention: Fibrinolysis treatment in women
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Fibrinolysis treatment in men
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Fibrinolysis treatment in women with bleeding
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Fibrinolysis treatment in men with bleeding
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Fibrinolysis treatment in women without bleeding
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Fibrinolysis treatment in men without bleeding
Number of subjects: 1000
Study: 19852962

Group type: EXPERIMENTAL
Intervention: TMC435 200 mg once daily for 5 days (patients)
Number of subjects: 55

Group type: COMPARATOR
Intervention: TMC435 (various doses) in healthy volunteers
Number of subjects: 55

Group type: COMPARATOR
Intervention: TMC435 200 mg twice daily or 100, 200, or 400 mg once daily (healthy volunteers)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: TMC435 (patients)
Number of subjects: 55
Study: 17284548

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise training (PRT)
Number of subjects: 31
Study: 17038828

Group type: EXPERIMENTAL
Intervention: Respiratory route of measles vaccine administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Respiratory route of measles vaccine administration (for vaccinees over 9 months of age)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Respiratory route of measles vaccine administration (Edmonston Zagreb strain)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerosol measles vaccine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerosolized EZ vaccine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Seroresponse among seropositive vaccinees
Number of subjects: 20
Study: 11901040

Group type: EXPERIMENTAL
Intervention: Biventricular stimulation (BVS)
Number of subjects: 53
Study: 10201304

Group type: EXPERIMENTAL
Intervention: Emergency MRI
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Emergency MRI after restoration of normal vertebral alignment
Number of subjects: 55
Study: 7485344

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control (no antibiotic therapy)
Number of subjects: 253
Study: 2050088

Group type: EXPERIMENTAL
Intervention: Calcium‐Sandoz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cal‐Sup
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Effercal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oscal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oscal Chewable
Number of subjects: 12
Study: 6840161

Group type: COMPARATOR
Intervention: Cadralazine (ISF 2469) 7.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cadralazine (ISF 2469) 15 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cadralazine (ISF 2469) 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cadralazine (ISF 2469) 30 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30520758

Group type: EXPERIMENTAL
Intervention: IPX203
Number of subjects: 0

Group type: COMPARATOR
Intervention: IR CD‐LD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rytary
Number of subjects: 0
Study: 29272208

Group type: EXPERIMENTAL
Intervention: Anti-obesity message with message fatigue
Number of subjects: 312
Study: 24944864

Group type: EXPERIMENTAL
Intervention: Advanced version of EMDR (1-2 hours intervention)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 22511836

Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Average signal strength (SS)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Relative SS change
Number of subjects: 474
Study: 19016798

Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair) in combination with depigmented SIT (Depigoid)
Number of subjects: 140

Group type: COMPARATOR
Intervention: SIT alone (Control)
Number of subjects: 140
Study: 17329468

Group type: EXPERIMENTAL
Intervention: Supported employment with cognitive training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Supported employment alone
Number of subjects: 44
Study: 14586662

Group type: EXPERIMENTAL
Intervention: Nasogastric tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gastrostomy tube
Number of subjects: 0
Study: 11475707

Group type: EXPERIMENTAL
Intervention: Philips Jordan HP510
Number of subjects: 78

Group type: COMPARATOR
Intervention: Braun Oral‐B D9
Number of subjects: 78
Study: 9126228

Group type: EXPERIMENTAL
Intervention: Screening by PSA (Hybritech Tandem E), DRE, and TRUS
Number of subjects: 9600

Group type: EXPERIMENTAL
Intervention: f-PSA/t-PSA ratio with a cut-off value of 0.20
Number of subjects: 9600

Group type: EXPERIMENTAL
Intervention: DRE
Number of subjects: 9600

Group type: EXPERIMENTAL
Intervention: TRUS, DRE, and PSA-driven biopsies
Number of subjects: 9600
Study: 8198093

Group type: EXPERIMENTAL
Intervention: Esophageal variceal ligation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 7
Study: 3591956

Group type: EXPERIMENTAL
Intervention: 150 g protein, 30 g fat, and 30 g carbohydrate (P)
Number of subjects: 5

Group type: COMPARATOR
Intervention: 150 g carbohydrate, 30 g fat, and 30 g protein (C)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 5
Study: 30338793

Group type: EXPERIMENTAL
Intervention: Cervical cancer patients (experimental group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervical cancer tissues (experimental group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR gene mutations (exon 19 and 21) in cervical cancer patients (experimental group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR gene mutations correlation with clinical features (experimental group)
Number of subjects: 0
Study: 27596559

Group type: EXPERIMENTAL
Intervention: imPACT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25499941

Group type: EXPERIMENTAL
Intervention: Legume consumption (more than 1 time per day)
Number of subjects: 9660

Group type: EXPERIMENTAL
Intervention: Legume consumption (frequency of consumption quartiles)
Number of subjects: 9660
Study: 22070527

Group type: EXPERIMENTAL
Intervention: Nebulized morphine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 6
Study: 20971252

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 726

Group type: COMPARATOR
Intervention: Aspirin with dipyridamole
Number of subjects: 726

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 726
Study: 18972076

Group type: EXPERIMENTAL
Intervention: Systane Lubricant Eye Drops
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Discontinuation of Systane Lubricant Eye Drops
Number of subjects: 107
Study: 15985559

Group type: EXPERIMENTAL
Intervention: Anti-H pylori treatment
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 795

Group type: COMPARATOR
Intervention: Control group (H pylori positive)
Number of subjects: 795
Study: 14727703

Group type: EXPERIMENTAL
Intervention: Polymer gel sock in conjunction with the removable rigid dressing
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal removable rigid dressing programme
Number of subjects: 16
Study: 10378544

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (42 microg per actuation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended-release oral theophylline (titrated to serum levels of 10 to 20 microg/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8681669

Group type: EXPERIMENTAL
Intervention: High-dose fenoterol (5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-dose fenoterol (1 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ipratropium bromide (0.5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1736585

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 6143849

Group type: EXPERIMENTAL
Intervention: Corgard (nadolol) 80 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Propranolol (control)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Obsidian (control)
Number of subjects: 17
Study: 30723876

Group type: EXPERIMENTAL
Intervention: Plazomicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plazomicin-based combinations
Number of subjects: 0
Study: 29943207

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) + conventional exercise (TG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional exercise (CG)
Number of subjects: 32
Study: 27036991

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (200 mg emtricitabine with 10 mg or 25 mg tenofovir alafenamide)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (200 mg emtricitabine with 200 mg or 300 mg tenofovir disoproxil fumarate)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Number of subjects: 668

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 668
Study: 24513620

Group type: EXPERIMENTAL
Intervention: Throwing-specific exercise (THROW)
Number of subjects: 13

Group type: COMPARATOR
Intervention: General exercise (RUN)
Number of subjects: 13
Study: 22931176

Group type: EXPERIMENTAL
Intervention: Texting (N = 45)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Eating (N = 45)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control (N = 96)
Number of subjects: 186
Study: 20192914

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (1000 microg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17011699

Group type: EXPERIMENTAL
Intervention: Sacropexy combined with Burch colposuspension (Group A)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No anti-incontinence procedure (Group B)
Number of subjects: 66
Study: 16281925

Group type: EXPERIMENTAL
Intervention: Neuropathy symptom score
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Neuropathy sign score
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Michigan Neuropathy Disability Score (MNDS)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Monofilament examination
Number of subjects: 142
Study: 12071996

Group type: EXPERIMENTAL
Intervention: 5% lidocaine and 0.5% phenylephrine ('co‐phenylcaine')
Number of subjects: 74

Group type: COMPARATOR
Intervention: 10% cocaine spray
Number of subjects: 74
Study: 9854437

Group type: EXPERIMENTAL
Intervention: Reinforcement based on voice loudness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no specific details provided)
Number of subjects: 0
Study: 7611550

Group type: EXPERIMENTAL
Intervention: Primaquine (0.5 mg/kg every other day for 16-19 weeks)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Chloroquine (5 mg/kg weekly for 16-19 weeks)
Number of subjects: 99
Study: 2227128

Group type: EXPERIMENTAL
Intervention: Cyclosporin therapy
Number of subjects: 98
Study: 325009

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30782399

Group type: EXPERIMENTAL
Intervention: Cotton ball packing
Number of subjects: 39

Group type: COMPARATOR
Intervention: No packing (control)
Number of subjects: 39
Study: 27541076

Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation (ECR) for 1 year
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 204
Study: 24961647

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Autologous fascial sling (AFS)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Xenograft sling (Pelvicol)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Comparison of AFS vs Pelvicol
Number of subjects: 201

Group type: COMPARATOR
Intervention: Comparison of AFS vs TVT
Number of subjects: 201
Study: 23243247

Group type: EXPERIMENTAL
Intervention: Phytase at normal usage levels (500 phytase units per kg of feed)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Phytase at 2X and 3X levels
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Carbohydrase mixture
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Phytase (1X, 2X, 3X)
Number of subjects: 540
Study: 21717823

Group type: EXPERIMENTAL
Intervention: Program B (modified elimination diet and phytonutrient-rich medical food)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Program B
Number of subjects: 8

Group type: COMPARATOR
Intervention: Program A (modified US Department of Agriculture food pyramid diet and rice protein powder supplement)
Number of subjects: 8
Study: 19290537

Group type: EXPERIMENTAL
Intervention: EGCG
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36